NCT05703282

A Study to Assess the Safety and Pharmacokinetics of AD-104-A

A Parallel, Open-Label, Single-Dose Administration, Phase 1 Clinical Study to Assess the Safety and Pharmacokinetics of AD-104-A in Healthy Adult Volunteers and Patients With Renal Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A

Detailed description

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-104-A in Healthy Adult Volunteers and Patients with Renal Impairment

Conditions

• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	AD-104-A	PO, Single-Dose, AD-104-A

Timeline

• Start date: 2023-03-13
• Primary completion: 2024-04-05
• Completion: 2024-04-05
• First posted: 2023-01-30
• Last updated: 2024-08-01

Locations

1 site across 1 country: South Korea